Shares of the TASER maker fell despite a strong earnings report.
Shares of Axon Enterprise (AXON -4.55%) were falling today after the company beat estimates in its first-quarter earnings report. Investors seemed to think the results weren’t enough to justify the company’s high valuation.
As a result, the stock was down 4.7% as of 2:57 p.m. ET.
Axon’s good but not-good-enough quarter
Axon, which makes the TASER electrical stun gun, as well as body and dashboard cameras for law enforcement, said that revenue in the quarter jumped 34% to $460.7 million, which was well ahead of estimates for $441.6 million. Growth was broad-based as TASER revenue jumped 33% to $178.7 million and software and sensors revenue rose 35% to $282 million.
Axon also showed off strong margin expansion, as adjusted gross margin improved from 59.9% to 63.2% and adjusted earnings per share rose from $0.88 to $1.15, beating estimates of $0.94. Axon’s strategy of selling hardware that connects to cloud software and services continued to pay off, driving strong growth on the top and bottom lines.
The company also talked up a new generative artificial intelligence (AI) software tool Draft One that will help police departments quickly write up reports, saving officers valuable time. Finally, it said it would acquire Dedrone, a drone and airspace security company, for an undisclosed sum.
Why Axon stock still fell
Axon also raised its guidance for the full year, calling for revenue growth of $1.94 billion to $1.99 billion, up from a range of $1.88 billion to $1.94 billion. This represented 26% growth at the midpoint.
Overall, the quarter seemed virtually flawless, but Axon stock has gotten expensive after surging more than 40% over the last year and investors seem to think a pullback was deserved. With a price-to-sales ratio of 12, the stock is still expensive, but the company’s execution has been superb.
Jeremy Bowman has positions in Axon Enterprise. The Motley Fool has positions in and recommends Axon Enterprise. The Motley Fool has a disclosure policy.